Company envisions research venue as well as site for sales, regional applications, and customer training.

Bruker opened its Singapore Center of Excellence at the Helios in Biopolis, providing sales and after-sales services for South East Asia. The facility includes a regional application and customer training center equipped with the scientific instrument maker’s latest systems.

Bruker Singapore says that it will also provide business and financial services for its operations in the region. The company now has about 45 staffers based in Singapore and says that it expects to hire 10 to 20 more people at the graduate to Ph.D. level as its business expands.

“With this major investment in our new Center of Excellence, Bruker Singapore has taken a major step forward to provide highest-level support and collaboration capabilities for our research, biopharma, clinical and advanced materials, and industrial customers in South East Asia,” states Frank H. Laukien, Ph.D., Bruker’s president and CEO.

George Tang, GM of Bruker Singapore, adds, “Bruker is also increasingly outsourcing some of its production to Singapore and South East Asia.” Besides Singapore, Bruker has operations in China, India, Japan, Malaysia, South Korea, Taiwan, and Thailand.

The company’s offerings include analytical and research systems for magnetic resonance (NMR, preclinical MRI, and EPR), atomic force microscopy, stylus and optical metrology, X-ray diffraction and crystallography, X-ray and spark-OES elemental analysis, life science and applied markets separations and mass spectrometry, as well as infrared and Raman spectroscopy.

The company finished the first quarter with net income of $11.3 million, down from $16.1 million in Q1 2010. It says the dip reflects expenses of acquisition-related inventory step-ups and other acquisition costs of $6.3 million, noncash amortization of $3.7 million, and stock-based compensation charges of $1.5 million. Revenue rose 29% from the year-ago quarter to $357 million from $277.7 million.

Previous articleCentella Partners with Cancer Research UK for Early Development of Newly Licensed Drug
Next articleSUNY at Buffalo Selects Sage-N’s Sorcerer Platform for Proteomics Work